急性心肌梗死后心源性休克患者的治疗

doi:10.3969/j.issn.1002-1949.2016.04.019

摘要
图/表
参考文献(39)
相关文章 (15)

全文: PDF (864 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要心源性休克是急性心肌梗死的严重并发症之一，具有发病率及致死率高的特点，严重威胁人类生命健康。目前，临床上急性心肌梗死后心源性休克的治疗方法，主要包括药物治疗、早期再灌注治疗及机械辅助循环治疗等。近年来，随着对机械辅助设施研究的深入与完善，机械辅助循环治疗在难治性心源性休克患者中的应用逐年增加，为难治性心衰患者提供生命支持。本文将对急性心肌梗死后心源性休克患者的治疗进展进行综述，希望对临床完善心源性休克患者救治流程及挽救患者生命提供完备思路。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王妍
	李碧澄
	杨爽
	孙鑫（综述）
	田野（审校）

收稿日期: 2016-01-12

基金资助:国家自然科学基金项目（81371709）

通讯作者: 田野（1965-），男，博士生导师，教授，E-mail: yetian@ems.hrbmu.edu.cn。

作者简介: 王妍（1990-），女，硕士研究生，E-mail:13212810963@163.com。

引用本文:

王妍，李碧澄，杨爽，孙鑫（综述），田野（审校）. 急性心肌梗死后心源性休克患者的治疗[J]. 中国急救医学, 2016, 36(4): 371-375.
WANG Yan, LI Bi-cheng, YANG Shuang, SUN Xin, TIAN Ye. Treatment of cardiogenic shock complicating acute myocardial infarction. Chinese Journal of Critical Care Medicine, 2016, 36(4): 371-375.

链接本文:

http://www.cnemergency.org.cn/CN/10.3969/j.issn.1002-1949.2016.04.019 或 http://www.cnemergency.org.cn/CN/Y2016/V36/I4/371

[1] Radovanovic D，Nallamothu BK，Seifert B，et al. Temporal trends in treatment of ST-elevation myocardial infarction among men and women in Switzerland between 1997 and 2011[J]. Eur Heart J Acute Cardiovasc Care，2012，1（3）:183-191. [2] Parakh N. Intraaortic balloon support for myocardial infarction with cardiogenic shock[J]. Indian Heart Journal，2012，64（14）:617-618. [3] Hochman JS，Sleeper LA，White HD，et al. One-year survival following early revascularization for cardiogenic shock[J]. J Am Med Associ，2001，285（2）:190-192. [4] Anderson ML，Peterson ED，Peng SA，et al. Differences in the profile，treatment，and prognosis of patients with cardiogenic shock by myocardial infarction classification a report from NCDR[J]. Circulation Cardiovascular Quality & Outcomes，2013，6（6）:708-715. [5] Yan BP，Clark DJ，Buxton B，et al. Clinical characteristics and early mortality of patients undergoing coronary artery bypass grafting compared to percutaneous coronary intervention: insights from the Australasian Society of Cardiac and Thoracic Surgeons（ASCTS）and the Melbourne Interventional Group（MIG）Registries[J].Heart Lung & Circulation，2009，18（3）:184-190. [6] Fu-Chun C，Sheng-Nan C，Jou-Wei L，et al. Coronary artery bypass graft surgery provides better survival in patients with acute coronary syndrome or ST- segment elevation myocardial infarction experiencing cardiogenic shock after percutaneous coronary intervention: a propensity score analysis[J]. J Thoracic & Cardiovasc Surg，2009，138（6）:1326-1330. [7] Darren M，Marie-Claude M，Hélène E，et al. Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction，Resuscitated Cardiac Arrest，and Cardiogenic Shock[J]. Jacc Cardiovascular Interventions，2013，6（2）:115-125. [8] Farrukh Hussain MD，Philipp RK，Ducas RA，et al. The ability to achieve complete revascularization is associated with improved in-hospital survival in cardiogenic shock due to myocardial infarction:Manitoba cardiogenic shock registry investigators[J]. Catheterization & Cardiovascular Interventions，2011，78（4）:540-548. [9] Jeong Hoon Y，Joo-Yong H，Pil Sang S，et al. Percutaneous coronary intervention for nonculprit vessels in cardiogenic shock complicating ST- segment elevation acute myocardial infarction[J].CritCare Med，2014，42（1）:17-25. [10] Kim U，Park JS，Kang SW，et al.Outcomes according to presentation with versus without cardiogenic shock in patients with left main coronary artery stenosis and acute myocardial infarction[J].Am J Cardiol，2012，110（1）:36-39. [11] Vis MM，Beijk MA，Grundeken MJ，et al. A systematic review and meta- analysis on primary percutaneous coronary intervention of an unprotected left main coronary artery culprit lesion in the setting of acute myocardial infarction[J]. Jacc Cardiovascular Interventions，2013，6（4）:317-324. [12] Alexopoulos D，Xanthopoulou I，Gkizas V，et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction[J]. Circulation Cardiovascular Interventions, 2012，5（6）:797-804. [13] Parodi G，Valenti R，Bellandi B，et al. Comparison of prasugrel and ticagrelor loading doses in ST- segment elevation myocardial infarction patients[J]. Jacc，2013，15:1601-1606. [14] Angiolillo DJ，Schneider DJ，Bhatt DL，et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition（CHAMPION）trials[J]. Journal of Thrombosis & Thrombolysis，2012，34（1）:44-55. [15] Iqbal J，Sumaya W，Tatman V，et al. Incidence and predictors of stent thrombosis:a single- centre study of 5，833 consecutive patients undergoing coronary artery stenting[J]. EuroIntervention，2013，209（1）: 62-69. [16] Tone S，Vlaar PJ，Horst ICVD，et al. Thrombus aspiration during primary percutaneous coronary intervention[J]. J Cardiovasc Med，2012，13（1）:231-241. [17] Bo L，Fröbert O，Olivecrona GK，et al. Outcomes 1 year after thrombus aspiration for myocardial infarction[J]. New Engl J Med，2014，371（12）:1111-1120. [18] Zia MI，Ghugre NR，Connelly KA，et al. Thrombus aspiration during primary percutaneous coronary intervention is associated with reduced myocardial edema ， hemorrhage ， microvascular obstruction and left ventricular remodeling[J]. J Cardiovasc Magn Reson，2012，14（13）:19. [19] Havel C，Arrich J，Losert H，et al. Vasopressors for hypotensive shock[J]. Ann Emerg Med，2013，61（3）:351-352. [20] Haruo T. Comparison of Dopamine and Norepinephrine in the treatment of shock[J]. Maedica - A J Clin Med，2010，54（5）:214-215. [21] Givertz M，Andreou CC，Colucci W. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force- frequency and relaxation- frequency relationships[J].Circulation，2007，115（10）:1218-1224. [22] Omerovic E，Råmunddal T，Albertsson P，et al. Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST- elevation myocardial infarction.[J]. Vascular Health & Risk Management，2010，6（9）:657-663. [23] Teerlink JR，Clarke CP，Saikali KG，et al. Dose- dependent augmentation of cardiac systolic function with the selective cardiac myosin activator，omecamtiv mecarbil: a first- in- man study[J].Lancet，2011，378（9792）:667-675. [24] Cleland JGF，Teerlink JR，Roxy S，et al. The effects of the cardiac myosin activator，omecamtiv mecarbil，on cardiac function in systolic heart failure: a double-blind，placebo-controlled，crossover，dose- ranging phase 2 trial[J]. Lancet，2011，378（9792）:676-683. [25] Teerlink JR，Felker GM，McMurray J，et al. A phase 2 study of intravenous Omecamtiv Mecarbil，a novel cardiac myosin activator，in patients with acute heart failure[J]. Eur Heart J，2013，34（97）:67-68. [26] Gheorghiade M，Blair JEA，Filippatos GS，et al. Hemodynamic，echocardiographic，and neurohormonal effects of istaroxime，a novel intravenous inotropic and lusitropic agent[J]. J Am Coll Cardiol，2008，51（23）:2276-2285. [27] Pöss J，Mahfoud F，Seiler S，et al. FGF-23 is associated with in⁃creased disease severity and early mortality in cardiogenic shock[J].Eur Heart J Acute Cardiovasc Care，2013，2（3）:211-218 [28] Sjauw K，Engstrom AM，Van-Der-Schaaf R，et al. A systematic review and meta- analysis of intra- aortic balloon pump therapy in ST- elevation myocardial infarction: should we change the guidelines[J]. Eur Heart J，2009，30（4）:459-468. [29] Roland P，Henning L，Michael S，et al. Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective，randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome[J]. Crit Care Med，2010，38（1）:152-160. [30] Holger T，Uwe Z，Franz- Josef N，et al. Intra- aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock（IABP-SHOCK Ⅱ）:final 12 month results of a randomised，open- label trial: The Lancet[J]. Lancet，2013，382（9905）:1638-1645. [31] Biswajit K ，Gregoric ID ，Basra SS ，et al. The percutaneous ventricular assist device in severe refractory cardiogenic shock[J]. J Am Coll Cardiol，2011，857（6）:688-696. [32] Daniel B，Howard C，Corinna B，et al. A randomized multicenter⁃clinical study to evaluate the safety and efficacy of the Tandem⁃Heart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock[J]. Am Heart J，2006，152（3）:469.e1-469.e8. [33] Stéphane MS，JérMe F，Armelle M，et al. Percutaneous left ventricular assistance in post cardiac arrest shock: comparison of intra aortic blood pump and IMPELLA Recover LP2.5[J]. Resuscitation，2013，84（5）:609-615. [34] O'Neill WW，Theodore S，Wohns DHW，et al. The current use of impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella registry[J]. J Interv Cardiol，2014，27（1）:1-11. [35] Jiunn-Jye S，Tzu-Hsien T，Fan-Yen L，et al. Early extracorporeal membrane oxygenator- assisted primary percutaneous coronary intervention improved 30- day clinical outcomes in patients with ST- segment elevation myocardial infarction complicated with profound cardiogenic shock[J]. Crit Care Med，2010，38（9）:1810-1847. [36] Tsao NW，Shih CM，Yeh JS，et al. Extracorporeal membrane oxygenation-assisted primary percutaneous coronary intervention may improve survival of patients with acute myocardial infarction complicated by profound cardiogenic shock[J]. J Crit Care，2012，27（5）:530.e1-11. [37] Pierre D，Ludovic F，Jean- Louis G，et al. Predictors of 30- day mortality and outcome in cases of myocardial infarction with cardiogenic shock treated by extracorporeal life support[J]. Eur J Cardiothorac Surg，2014，45（1）:47-54. [38] Pengyu M，Zaiwang Z，Tieying S，et al. Combining ECMO with IABP for the treatment of critically ill adult heart failure patients[J]. Heart Lung Circ，2014，23（4）:363-368. [39] Madershahian N，Wippermann J，Liakopoulos O，et al. The acute effect of IABP-induced pulsatility on coronary vascular resistance and graft flow in critical ill patients during ECMO[J]. J Cardiovasc Surg（Torino），2011，52（3）:411-418.